Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2008 1
2012 1
2013 2
2015 2
2017 1
2018 2
2019 4
2020 3
2021 9
2022 4
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F, Ylösmäki E, Chiaro J, Giannoula Y, Long M, Fusciello M, Feola S, Martins B, Feodoroff M, Antignani G, Russo S, Kari O, Lee M, Järvinen P, Nisen H, Kreutzman A, Leusen J, Mustjoki S, McWilliams TG, Grönholm M, Cerullo V. Hamdan F, et al. Among authors: ylosmaki e. J Immunother Cancer. 2021 Aug;9(8):e003000. doi: 10.1136/jitc-2021-003000. J Immunother Cancer. 2021. PMID: 34362830 Free PMC article.
Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma.
Carpi S, Polini B, Fogli S, Podestà A, Ylösmäki E, Cerullo V, Romanini A, Nieri P. Carpi S, et al. Among authors: ylosmaki e. Expert Rev Mol Diagn. 2020 Jan;20(1):19-30. doi: 10.1080/14737159.2020.1696194. Epub 2019 Nov 27. Expert Rev Mol Diagn. 2020. PMID: 31747311 Review.
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V. Feola S, et al. Among authors: ylosmaki e. Front Immunol. 2022 Apr 14;13:826164. doi: 10.3389/fimmu.2022.826164. eCollection 2022. Front Immunol. 2022. PMID: 35493448 Free PMC article.
Artificially cloaked viral nanovaccine for cancer immunotherapy.
Fusciello M, Fontana F, Tähtinen S, Capasso C, Feola S, Martins B, Chiaro J, Peltonen K, Ylösmäki L, Ylösmäki E, Hamdan F, Kari OK, Ndika J, Alenius H, Urtti A, Hirvonen JT, Santos HA, Cerullo V. Fusciello M, et al. Among authors: ylosmaki e. Nat Commun. 2019 Dec 17;10(1):5747. doi: 10.1038/s41467-019-13744-8. Nat Commun. 2019. PMID: 31848338 Free PMC article.
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S, Feola S, Capasso C, Laustio N, Groeneveldt C, Ylösmäki EO, Ylösmäki L, Martins B, Fusciello M, Medeot M, Tagliamonte M, Chiaro J, Hamdan F, Peltonen K, Ranki T, Buonaguro L, Cerullo V. Tähtinen S, et al. Among authors: ylosmaki eo. Cancer Res. 2020 Jun 15;80(12):2575-2585. doi: 10.1158/0008-5472.CAN-19-2062. Epub 2020 Feb 27. Cancer Res. 2020. PMID: 32107211
Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy.
Ylösmäki L, Polini B, Carpi S, Martins B, Smertina E, Feola S, Fusciello M, Peltonen K, Nieri P, Ylösmäki E, Cerullo V. Ylösmäki L, et al. Among authors: ylosmaki e. PLoS One. 2019 Oct 23;14(10):e0224072. doi: 10.1371/journal.pone.0224072. eCollection 2019. PLoS One. 2019. PMID: 31644552 Free PMC article.
28 results